Pirfenidone represents the first concrete chance of slowing down disease progression. The result on increasing progression free of charge survival, as demonstrated in three mixed studies, coupled with an acceptable safety account, opens up a new path for better administration of IPF. Last year Cipla launched the world’s first generic Bosentan, for the treatment of Pulmonary Arterial Hypertension. With the launch of Pirfenex, Cipla reaffirms its leadership in the respiratory arena with services and products in 8 therapeutic areas viz.‘Finally, the lesson learnt from the product quality and outcomes framework is that people need to discover what the chance costs are of applying the brand new scheme, they conclude. ‘If clinicians and hospitals allocate scarce resources to incentive schemes targeted at improving a particular group of conditions, there is a risk that additional clinical conditions and procedures will get less interest and their outcomes will not be improved. ‘This brand-new model rewards healthcare providers if they deliver top quality care and improvements in care and attention delivery,’ says Patrick Geraghty, Blue Cross CEO and president.’ In the shared incentive model, physicians, treatment centers and hospitals continue steadily to get paid a simple rate, as in the original ‘fee for provider’ model.